| abstract |
THE DISCLOSED INVENTION IS COMPOUNDS REPRESENTED BY THE FORMULA AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION, BASIC ADDITION AND QUARTERNARY AMINE SALTS THEREOF AND PHARMACEUTICALLY ACCEPTABLE SOLVATES THEREOF, WHEREIN EACH Z IS INDEPENDENTLY TETIARY BUTYL, PHENYL, NAPHTHYL OR ADAMANTYL; SUBSTITUTED PHENYL, WHEREIN THE SUBSTITUENTS ARE ONE OR MORE OF HALOGEN, LOWER ALKOXY, PHENOXY, NITRILE, NITRO, PHENYLSULFONYL, LOWERALKYL-SULFONYL, OXAZOL-2-YL, LOWER ALKANOYL, BENZOYL, LOWER ALKOXYCARBONYL, LOWER ALKYL, LOWER ALKYLTHIO, PHENYL, PHENYLAMINOTHIOCARBONYL, OR LOWER ALKYLAMINOTHIOCARBONYL; 4 OR 6 MEMBERED UNSUBSTITUTED OR SUBSTITUTED HETEROCYCLIC RING CONTAINING AT LEAST ONE NITROGEN WITH THE REMAINING MEMBER OF THE RING BEING AT LEAST ONE CARBON, AND OPTIONALLY SULFUR OR OXIGEN, WHEREIN THE SUBSTITUENTS ARE ONE OR MORE OF CARBOXYL, HYDROXYMETHYL, LOWER ALKYL, LOWERALKYLCARBONYL OR ARYL LOWER ALKYL; X AND Y ARE EACH INDEPENDENTLY A BOND, -O-,EACH Q IS INDEPENDENTLY A DIVALENT SUBSTITUTED OR UNSUBSTITUTED, STRAIGHT OR BRANCHED CHAIN LOWER ALKANEDIYL, LOWER ALKANEDILY-CYCLOALKANEDIYL-LOWER ALKANEDIYL, LOWER ALKENEDIYL, PHENYLENE, DIHYDROFURANDIYL, TETRAHYDROFURANDIYL,TETRAHYDROPYRANDIYL, OR LOWERALKANEDIYL-TETRAHYDROFURANDIYL-LOWERALKANEDIYL, WHEREIN THE SUBSTITUENTS ARE ONE OR MORE OF HYDROXY, EPOXY, FLUORINE, CHLORINE, AZIDE, OR AMINO; W IS A MONOVALENT SUBSTITUTED OR UNSUBSTITUTED ARYL GROUP OR A HETEROCYCLIC SINGLE OR FUSED RING CONTAINING FROM 4 TO 10 RING ATOMS, AT LEAST ONE HETERO ATOM OF WHICH IS A NITROGEN ATOM AND THE REMAINING RING ATOMS BEING AT LEAST ONE CARBON AND OPTIONALLY SULFUR OR OXYGEN, WHEREIN THE SUBSTITUENTS ARE ONE OR MORE OF HYDROXY, OXO AMINO, CARBAMOYL, CARBOXYL, NITRILE, NITRO,LOWER ALKOXY CARBONYL, HALOGEN, SULFAMYL, LOWER ALKYL, LOWER ALKYLTHIO, LOWER ALKOXY, HYDROXYLOWERALKYL, LOWER ALKOXYCARBONYLLOWERALKYL, AMINO LOWERALKYL, CARBOXYLOWERALKYL, GUANIDINO, THIOUREIDO, LOWER ALKYLSULFONYLAMINO, AMINOCARBONYLLOWERALKYL, ALLYLOXYCARBONYLMETHYL OR CARBAMOYLOXYLOWERALKYL; WITH THE PROVISO THAT W CANNOT BE SUBSTITUTED OR UNSUBSTITUTED ISOXAZOLYL, AND W'' IS DIVALENT W. THE COMPOUNDS HAVE ANTIVIRAL ACTIVITY, ANTIINFLAMMATORY ACTIVITY AND ARE PAF INHIBITORS. |